| RANK Signaling-based New Drug Targets for Osteoporosis |
| RANK 신호전달계에 근거한 골다공증 치료제 타겟 |
| 최한경,김경희,신지혜,장현덕,이수영12 |
| 이화여자대학교 생명약학부, 이화여자대학교 생명과학과1, 이화여자대학교 바이오융합과학과2 |
|
|
| Abstract |
|
Increased osteoclastic bone resorption causes the loss in bone density observed in human diseases such as osteoporosis
and arthritis. The discovery of the RANKL/RANK axis as the final effector of bone destruction has generated great
expectations regarding the potential of some antagonists for the treatment of patients with various metabolic and
inflammatory bone disorders. The signaling cascades initiated by RANKL uncover several new classes of antiresorptive
therapeutic targets. Unraveling the entire RANK signaling networks will be beneficial for the development of new
generations of therapeutics with higher efficacy and fewer side effects.
[Korean Journal of Bone Metabolism, 16(2): 65-69, 2009] |
| Key Words:
RANKL, RANK, Osteoclast, Bone resorption, Osteoporosis |
|
PDF Links
Full text via DOI
Download Citation
